北京清辉联诺生物科技有限责任公司于2018年成立，是一家基于新型免疫细 胞——γδT细胞开发创新性免疫药物的生物技术公司，致力于全面挖掘γδT细胞/ BTN 免疫机制在癌症、自身免疫疾病的治疗潜力。 目前公司围绕γδT细胞已布局异体现货型细胞药、新靶点小分子药等研发管 线，已推进3款异体细胞治疗药物进入人体试验研究阶段，在脑肿瘤、肝癌、急性髓 系白血病等领域证明了γδT细胞强大的治疗潜力。 2025年3月，通用型γδT细胞注射液QH104A获美国FDA恶性脑胶质瘤适应症 孤儿药资格认定。凭借原创核心技术优势，公司与多家知名药物开发企业建立了良 好合作关系，正快速推进项目向临床和产业转化。截至目前，清辉联诺已获得近2亿 元融资。

 Beijing Unicet Biotechnology Co., Ltd., founded in 2018, is a biotech focused  on the development of innovative immunotherapies based on a novel immune cell  type: γδ T cells. It is dedicated to exploring the therapeutic potential of γδ T cell/ BTN immune mechanisms in cancer and autoimmune diseases. Currently, Unicet  has established research pipelines for allogeneic cell therapies and novel small  molecule drugs targeting γδ T/BTN immune axis. Three allogeneic cell therapies  are in clinical trials for brain tumors, liver cancer, and acute myeloid leukemia,  demonstrating strong therapeutic potential. In March 2025, its universal γδ T cell  injection QH104A was granted Orphan Drug Designation by the U.S. FDA for the  treatment of malignant gliomas. Leveraging proprietary technology, the company  collaborates with leading pharmaceutical firms to accelerate clinical and industrial  development. To date, Unicet has secured approximately RMB 200 million in financing.

地址：北京市昌平区生命科学园生命园路20号院7号楼3层

Floor 3, Building 7, Courtyard 20, Shengmingyuan Road,

Life Science Park, Changping District, Beijing 102206,

China